Neurocrine Biosciences Inc (NBIX): who owns it and who trades it
As of Nov 16, 2026, NBIX insiders reported 50 open-market sales worth $77.4M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kevin Charles Gorman (Director), with $37.8M. 7 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Neurocrine Biosciences
From the latest filingsOverall: more buying than selling. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns NBIX
773 funds and institutions reported NBIX shares worth $17.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 13.6%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 13.71M | 13.64% | $2.3B | +2% |
| JPMorgan Chase & Co | 6.40M | 6.36% | $1.1B | – |
| Dodge & Cox | 5.58M | 5.55% | $941M | +2% |
| Vanguard Portfolio Management LLC | 4.97M | 4.95% | $838M | +5% |
| Vanguard Capital Management LLC | 4.55M | 4.52% | $766M | +1% |
| State Street Corp | 4.39M | 4.36% | $739M | +1% |
| AQR Capital Management LLC | 3.82M | 3.80% | $643M | -23% |
| Renaissance Technologies LLC | 2.34M | 2.32% | $394M | -3% |
| Geode Capital Management, LLC | 2.14M | 2.13% | $360M | +0% |
| Two Sigma Investments, LP | 2.08M | 2.06% | $350M | -32% |
| Vestal Point Capital, LP | 1.88M | 1.87% | $317M | +50% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.49M | 1.49% | $252M | No change |
| Morgan Stanley | 1.32M | 1.31% | $222M | +8% |
| Rtw Investments, LP | 1.27M | 1.26% | $214M | +19% |
| Northern Trust Corp | 1.26M | 1.25% | $212M | +1% |
| Invesco Ltd. | 1.08M | 1.07% | $182M | +203% |
| Charles Schwab Investment Management Inc | 974,279 | 0.97% | $164M | +8% |
| Sixth Street Partners Management Company, L.P. | 974,279 | 0.97% | $164M | – |
| Norges Bank | 973,880 | 0.97% | $164M | – |
| First Trust Advisors LP | 923,125 | 0.92% | $156M | -4% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, NBIX insiders reported $0 of open-market purchases and $77.4M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | George J Morrow | Director | Sale plan | 100 | $158.18 | $15.8K | Form 4 |
| Nov 3, 2026 | George J Morrow | Director | Sale plan | 100 | $162.05 | $16.2K | Form 4 |
| Nov 3, 2026 | George J Morrow | Director | Sale plan | 600 | $163.71 | $98.2K | Form 4 |
| Nov 3, 2026 | George J Morrow | Director | Sale plan | 1,226 | $164.74 | $202K | Form 4 |
| Nov 3, 2026 | George J Morrow | Director | Sale plan | 908 | $165.71 | $150K | Form 4 |
| Nov 3, 2026 | George J Morrow | Director | Sale plan | 1,466 | $166.77 | $244K | Form 4 |
| Nov 3, 2026 | George J Morrow | Director | Sale plan | 1,500 | $167.72 | $252K | Form 4 |
| Nov 3, 2026 | George J Morrow | Director | Sale plan | 1,300 | $168.53 | $219K | Form 4 |
| Nov 2, 2026 | George J Morrow | Director | Sale plan | 1,900 | $144.98 | $275K | Form 4 |
| Nov 2, 2026 | George J Morrow | Director | Sale plan | 4,300 | $145.86 | $627K | Form 4 |
| Nov 2, 2026 | George J Morrow | Director | Sale plan | 1,300 | $146.76 | $191K | Form 4 |
| Oct 30, 2026 | George J Morrow | Director | Sale plan | 300 | $149.00 | $44.7K | Form 4 |
| Sep 14, 2026 | David W. Boyer | Chief Corp. Affairs Offi | Sale plan | 826 | $157.45 | $130K | Form 4 |
| Sep 14, 2026 | Matt Abernethy | CFO | Sale plan | 2,311 | $157.20 | $363K | Form 4 |
| Sep 9, 2026 | Eric Benevich | Chief Commercial Officer | Sale plan | 2,154 | $154.61 | $333K | Form 4 |
| Jul 28, 2026 | Leslie V Norwalk | Director | Sale plan | 1,250 | $182.01 | $228K | Form 4 |
| Jul 10, 2026 | Ingrid Delaet | Chief Regulatory Officer | Sale plan | 4,367 | $181.02 | $791K | Form 4 |
| Jul 9, 2026 | Darin Lippoldt | Chief Legal Officer | Sale plan | 10,000 | $179.60 | $1.8M | Form 4 |
| Jul 9, 2026 | Ingrid Delaet | Chief Regulatory Officer | Sale plan | 8,433 | $178.72 | $1.5M | Form 4 |
| Jul 8, 2026 | Ingrid Delaet | Chief Regulatory Officer | Sale plan | 2,737 | $178.54 | $489K | Form 4 |
| Jul 7, 2026 | Ingrid Delaet | Chief Regulatory Officer | Sale plan | 3,401 | $178.57 | $607K | Form 4 |
| Jun 29, 2026 | Darin Lippoldt | Chief Legal Officer | Sale plan | 1,690 | $170.81 | $289K | Form 4 |
| Jun 29, 2026 | Darin Lippoldt | Chief Legal Officer | Sale plan | 8,110 | $170.03 | $1.4M | Form 4 |
| Jun 26, 2026 | Darin Lippoldt | Chief Legal Officer | Sale plan | 200 | $169.57 | $33.9K | Form 4 |
| Jun 5, 2026 | Stephen A Sherwin | Director | Sale plan | 7,883 | $163.81 | $1.3M | Form 4 |
| Jun 5, 2026 | Stephen A Sherwin | Director | Sale plan | 2,549 | $164.44 | $419K | Form 4 |
| Jun 5, 2026 | Stephen A Sherwin | Director | Sale plan | 6,896 | $165.79 | $1.1M | Form 4 |
| Jun 5, 2026 | Stephen A Sherwin | Director | Sale plan | 5,829 | $166.56 | $971K | Form 4 |
| Jun 5, 2026 | Stephen A Sherwin | Director | Sale plan | 1,843 | $167.31 | $308K | Form 4 |
| Jun 4, 2026 | Leslie V Norwalk | Director | Sale plan | 1,250 | $168.06 | $210K | Form 4 |
| Jun 2, 2026 | Julie Cooke | Chief Human Resources Of | Sale plan | 3,520 | $158.59 | $558K | Form 4 |
| Jun 2, 2026 | Julie Cooke | Chief Human Resources Of | Sale plan | 9,521 | $157.62 | $1.5M | Form 4 |
| Jun 2, 2026 | Julie Cooke | Chief Human Resources Of | Sale plan | 4,216 | $156.77 | $661K | Form 4 |
| Jun 2, 2026 | Julie Cooke | Chief Human Resources Of | Sale plan | 5,466 | $155.46 | $850K | Form 4 |
| Jun 2, 2026 | Julie Cooke | Chief Human Resources Of | Sale plan | 14,214 | $154.83 | $2.2M | Form 4 |
| Jun 1, 2026 | Jude Onyia | Chief Scientific Officer | Sale plan | 11,000 | $160.25 | $1.8M | Form 4 |
| May 29, 2026 | Ingrid Delaet | Chief Regulatory Officer | Sale plan | 2,261 | $156.71 | $354K | Form 4 |
| May 27, 2026 | Jude Onyia | Chief Scientific Officer | Sale plan | 11,000 | $155.53 | $1.7M | Form 4 |
| May 26, 2026 | David W. Boyer | Chief Corp. Affairs Offi | Sale plan | 3,888 | $156.64 | $609K | Form 4 |
| May 19, 2026 | Kevin Charles Gorman | Director | Sale plan | 245,088 | $154.33 | $37.8M | Form 4 |
| May 15, 2026 | Richard F Pops | Director | Sale plan | 15,000 | $157.65 | $2.4M | Form 4 |
| May 12, 2026 | Leslie V Norwalk | Director | Sale plan | 3,810 | $155.01 | $591K | Form 4 |
| Jan 16, 2026 | Kyle Gano | CEO | Sale plan | 1,812 | $132.71 | $240K | Form 4 |
| Jan 16, 2026 | Kyle Gano | CEO | Sale plan | 34,588 | $132.70 | $4.6M | Form 4 |
| Dec 16, 2025 | Leslie V Norwalk | Director | Sale plan | 1,190 | $155.09 | $185K | Form 4 |
| Dec 15, 2025 | Leslie V Norwalk | Director | Sale plan | 5,000 | $152.23 | $761K | Form 4 |
| Dec 8, 2025 | Darin Lippoldt | Chief Legal Officer | Sale plan | 4,376 | $159.65 | $699K | Form 4 |
| Dec 3, 2025 | Gary A Lyons | Director | Sale plan | 15,000 | $152.61 | $2.3M | Form 4 |
| Nov 28, 2025 | Eric Benevich | Chief Commercial Officer | Sale plan | 5,970 | $151.74 | $906K | Form 4 |
| Nov 25, 2025 | George J Morrow | Director | Sale plan | 15,000 | $143.37 | $2.2M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Kevin Charles Gorman | Director | – | $37.8M | May 19, 2026 |
| Julie Cooke | Chief Human Resources Officer | – | $5.8M | Jun 2, 2026 |
| Kyle Gano | Chief Executive Officer, Director | – | $4.8M | Jan 16, 2026 |
| George J Morrow | Director | – | $4.5M | Nov 3, 2026 |
| Darin Lippoldt | Chief Legal Officer | – | $4.2M | Jul 9, 2026 |
| Stephen A Sherwin | Director | – | $4.1M | Jun 5, 2026 |
| Ingrid Delaet | Chief Regulatory Officer | – | $3.7M | Jul 10, 2026 |
| Jude Onyia | Chief Scientific Officer | – | $3.5M | Jun 1, 2026 |
| Richard F Pops | Director | – | $2.4M | May 15, 2026 |
| Gary A Lyons | Director | – | $2.3M | Dec 3, 2025 |
| Leslie V Norwalk | Director | – | $2M | Jul 28, 2026 |
| Eric Benevich | Chief Commercial Officer | – | $1.2M | Sep 9, 2026 |
| David W. Boyer | Chief Corp. Affairs Officer | – | $739K | Sep 14, 2026 |
| Matt Abernethy | Chief Financial Officer | – | $363K | Sep 14, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NBIX short interest
Moderate short interest. 5.8% of NBIX shares are sold short: about 1 share in 17. Over the last 12 reports the number of shares short went up 14%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.90M NBIX shares were sold short, 5.8% of the shares outstanding, down 8.5% from the report before. At the average daily volume of 1.09M shares, buying them all back would take about 5.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.90M | 5.83% | -8% | 1.09M | 5.4 |
| Oct 15, 2026 | 6.45M | 6.34% | +10% | 1.42M | 4.5 |
| Sep 30, 2026 | 5.85M | 5.76% | +18% | 1.48M | 4.0 |
| Sep 15, 2026 | 4.96M | 4.88% | -2% | 924,045 | 5.4 |
| Aug 31, 2026 | 5.06M | 4.97% | +11% | 1.09M | 4.7 |
| Aug 14, 2026 | 4.55M | 4.48% | +4% | 1.33M | 3.4 |
| Jul 31, 2026 | 4.39M | 4.32% | -18% | 1.46M | 3.0 |
| Jul 15, 2026 | 5.33M | 5.31% | -4% | 1.09M | 4.9 |
| Jun 30, 2026 | 5.53M | 5.50% | -3% | 1.32M | 4.2 |
| Jun 15, 2026 | 5.69M | 5.66% | +3% | 1.13M | 5.0 |
| May 29, 2026 | 5.53M | 5.50% | +7% | 1.11M | 5.0 |
| May 15, 2026 | 5.16M | 5.13% | -14% | 1.40M | 3.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded NBIX
Since Nov 17, 2024, 1 member of Congress reported 1 purchase and 1 sale of NBIX. The latest was a sale by Lisa C. McClain on Jun 17, 2025, reported Aug 13, 2025.
Purchases 1Sales 1
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Jun 17, 2025 | Lisa C. McClain (R-MI) | Partial sale | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jun 11, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Neurocrine Biosciences company events
Neurocrine Biosciences filed 9 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 2, 2026.
- Nov 2, 2026ResultsReleased financial results. Filing
- Sep 28, 2026LeadershipThe Board of Directors of Neurocrine Biosciences, Inc. appointed Eiry W. Roberts, M.D., to succeed Sanjay Keswani, M.D., as the Company’s Chief Medical Officer, effective September 28, 2026. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- May 28, 2026LeadershipAs discussed below in Item 5.07, Neurocrine Biosciences, Inc. held its 2026 Annual Meeting of Stockholders at which the Company’s stockholders approved an amendment of the Company’s 2025 Equity Incentive Plan. Filing
- May 18, 2026DealThe information set forth in the Introductory Note of this Report is incorporated by reference into this Item 2.01. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 6, 2026AgreementNeurocrine Biosciences, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger by and among Neurocrine, Sigma Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Neurocrine, and Soleno Therapeutics, Inc., a Delaware corporation. Filing
- Feb 11, 2026ResultsReleased financial results. Filing
- Nov 24, 2025LeadershipAs previously disclosed, Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc., effective June 2, 2025 . In connection with this transition, the Company and Dr. Roberts entered into an Amended and Restated Employment Agreement, effective… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Neurocrine Biosciences financials
Famous investors that hold NBIX
7 of the 50 well-known investors we track reported holding NBIX in their latest 13F filing. The largest position is Jim Simons's, worth $326M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.30M | $326M | 0.4% | -2% |
| Israel Englander · Millennium Management | Q3 2026 | 368,839 | $52.3M | 0.0% | +3084% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 206,386 | $29.3M | 0.1% | +0% |
| Jeremy Grantham · GMO | Q3 2026 | 147,354 | $20.9M | 0.0% | +103% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 36,382 | $5.2M | 0.0% | +207% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 16,467 | $2.3M | 0.0% | -88% |
| Lee Ainslie · Maverick Capital | Q3 2026 | 3,856 | $547K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named NBIX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 30, 2026 | Vanguard Portfolio Management | 13G | 5.0% |
| Oct 30, 2026 | Vanguard Portfolio Management | 13G | 5.0% |
| Oct 15, 2026 | JPMORGAN CHASE & CO. | 13G/A | 5.2% |
| Oct 15, 2026 | JPMORGAN CHASE & CO. | 13G/A | 5.2% |
Questions about Neurocrine Biosciences Inc (NBIX) stock
Who owns the most NBIX stock?
The largest reported owner of Neurocrine Biosciences Inc (NBIX) is BlackRock, Inc., with 13.6% of the company. In total, 773 funds and institutions reported holding NBIX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are NBIX insiders buying or selling?
In the last 12 months, NBIX insiders reported no open-market purchases and 50 sales worth $77.4M. The latest trade was on Nov 3, 2026. See every trade.
What is the short interest in NBIX?
As of Oct 30, 2026, 5.90M NBIX shares were sold short, 5.8% of the shares outstanding, down 8.5% from the report before. At the average daily volume of 1.09M shares, buying them all back would take about 5.4 trading days (days to cover). See the history.
Have members of Congress traded NBIX?
Yes. 1 member of Congress reported 1 purchase and 1 sale of NBIX since Nov 17, 2024. The latest was reported on Aug 13, 2025. See the trades.
Which famous investors hold NBIX?
7 of the 50 well-known investors we track reported NBIX in their latest 13F filing, including Jim Simons, Israel Englander, Ray Dalio. The largest position is worth $326M. See all holders.
Executive pay
Neurocrine Biosciences's chief executive was paid a total of $6.9M for the year ended Dec 31, 2025. In the last 12 months, Neurocrine Biosciences's executives and directors bought no stock on the open market and sold $77.4M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.